Immunomodulation with dendritic cells and donor lymphocyte infusion converge to induce graft vs neuroblastoma reactions without GVHD after allogeneic bone marrow transplantation

British Journal of Cancer

Volumn 103, Issue 10, 2010, Pages 1597-1605

  Ash, S ^a   Stein, J ^a   Askenasy, N ^a   Yaniv, I ^a  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

allogeneic bone marrow transplantation; dendritic cells; donor lymphocyte infusion; graft vs host disease; graft vs tumour reaction; neuroblastoma

Indexed keywords

ADAPTIVE IMMUNITY; ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DENDRITIC CELL; DISEASE SEVERITY; DONOR LYMPHOCYTE INFUSION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS NEUROBLASTOMA TUMOR; IMMUNOGENICITY; LYMPHOCYTOPENIA; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; T CELL DEPLETION; TUMOR IMMUNITY;

ADOPTIVE TRANSFER; ANIMALS; BONE MARROW TRANSPLANTATION; CHILD; DENDRITIC CELLS; FEMUR; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HUMANS; IMMUNOCOMPROMISED HOST; LIVER; LYMPHOCYTE DEPLETION; LYMPHOCYTE TRANSFUSION; LYMPHOPENIA; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; NEUROBLASTOMA; SKIN; TIBIA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 78149465322     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605924     Document Type: Article

References (57)

1. Anderson LD Jr, Savary CA, Mullen CA (2000) Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-vs-tumor activity without exacerbating graft-vs-host disease. Blood 95: 2426-2433
2. Asavaroengchai W, Kotera Y, Koike N, Pilon-Thomas S, Mulé JJ (2004) Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells. Biol Blood Marrow Transplant 10: 524-533
3. Asavaroengchai W, Kotera Y, Mule JJ (2002) Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci USA 99: 931-936
4. Ash S, Gigi V, Askenasy N, Fabian I, Stein J, Yaniv I (2009) Graft vs neuroblastoma reaction is efficiently elicited by allogeneic bone marrow transplantation through cytolytic activity in the absence of GVHD. Cancer Immunol Immunother 58: 2073-2084
5. Askenasy N, Farkas DL (2003) In vivo imaging studies of the effect of recipient conditioning, donor cell phenotype and antigen disparity on homing of haematopoietic cells to the bone marrow. Br J Haematol 120: 505-515
6. Banchereau J, Palucka AK (2005) Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5: 296-306
7. Bausero M, Panoskaltsis-Mortari A, Blazar BR, Katsanis E (1995) Effective immunization against murine neuroblastoma using transduced tumor cells secreting GM-CSF and interferon-g. Cancer Gene Ther 2: 309-317
8. Blazar BR, Taylor PA, Snover DC, Sehgal SN, Vallera DA (1993) Murine recipients of fully mismatched donor marrow are protected from lethal graft-vs-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome. J Immunol 151: 5726-5741
9. Bohana-Kashtan O, Morisot S, Hildreth R, Brayton C, Levitsky HI, Civin CI (2009) Selective reduction of graft-vs-host disease-mediating human T cells by ex vivo treatment with soluble Fas ligand. J Immunol 183: 696-705
10. Borrello I, Sotomayor EM, Rattis FM, Cooke SK, Gu L, Levitsky HI (2000) Sustaining the graft-vs-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood 95: 3011-3019
11. Caruso DA, Orme LM, Amor GM, Neale AM, Radcliff FJ, Downie P, Tang ML, Ashley DM (2005) Results of a phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with stage 4 neuroblastoma. Cancer 103: 1280-1291
12. Chakraverty R, Eom HS, Sachs J, Buchli J, Cotter P, Hsu R, Zhao G, Sykes M (2006) Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-vs-leukemia responses following delayed donor leukocyte infusions. Blood 108: 2106-2113
13. Chakraverty R, Sykes M (2007) The role of antigen-presenting cells in triggering graft-vs-host disease and graft-vs-leukemia. Blood 110: 9-17
14. Cho BK, Rao VP, Ge Q, Eisen HN, Chen J (2000) Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells. J Exp Med 192: 549-556
15. Cooke KR, Hill GR, Crawford JM, Bungard D, Brinson YS, Delmonte J Jr, Ferrara JL (1998) Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-vs-host disease. J Clin Invest 102: 1882-1891
16. Cooper MJ, Hutchins GM, Mennie RJ, Israel MA (1990) Beta 2-microglobulin expression in human embryonal neuroblastoma reflects its developmental regulation. Cancer Res 50: 3694-3700
17. Coze C, Aalto-Setala K, Brenner M, Chiang Y (1995) Characteristics and immunomodulatory properties of human neuroblastoma cells after retrovirus-mediated gene transfer of the cytokine genes IL-2 and IFN-gamma. Transgenics 1: 585-595
18. Demirer T, Barkholt L, Blaise D, Pedrazzoli P, Aglietta M, Carella AM, Bay JO, Arpaci F, Rosti G, Gurman G, Niederwieser D, Bregni M (2008) Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. Nat Clin Pract Oncol 5: 256-267
19. Eto M, Kamiryo Y, Takeuchi A, Harano M, Tatsugami K, Harada M, Kiyoshima K, Hamaguchi M, Teshima T, Tsuneyoshi M, Yoshikai Y, Naito S (2008) Posttransplant administration of cyclophosphamide and donor lymphocyte infusion induces potent antitumor immunity to solid tumor. Clin Cancer Res 14: 2833-2840
20. Feuerer M, Beckhove P, Bai L, Solomayer EF, Bastert G, Diel IJ, Pedain C, Oberniedermayr M, Schirrmacher V, Umansky V (2001) Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 7: 452-458
21. Fish JD, Grupp SA (2008) Stem cell transplantation for neuroblastoma. Bone Marrow Transplant 41: 159-165
22. Fukui J, Inaba M, Ueda Y, Miyake T, Hosaka N, Kwon AH, Sakaguchi Y, Tsuda M, Omae M, Kamiyama Y, Ikehara S (2007) Prevention of graft-vs-host disease by intra-bone marrow injection of donor T cells. Stem Cells 25: 1595-1601
23. Geiger J, Hutchinson R, Hohenkirk L, Mckenna E, Chang A, Mule J (2000) Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells. Lancet 356: 1163-1165
24. Ghosh A, Koestner W, Hapke M, Schlaphoff V, Länger F, Baumann R, Koenecke C, Cornberg M, Welte K, Blazar BR, Sauer MG (2009) Donor T cells primed on leukemia lysate-pulsed recipient APCs mediate strong graft-vs-leukemia effects across MHC barriers in full chimeras. Blood 113: 4440-4448
25. Hu HM, Poehlein CH, Urba WJ, Fox BA (2002) Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res 62: 3914-3919
26. Jing W, Gershan JA, Johnson BD (2009) Depletion of CD4 T cells enhances immunotherapy for neuroblastoma after syngeneic HSCT but compromises development of antitumor immune memory. Blood 113: 4449-4457
27. Jing W, Orentas RJ, Johnson BD (2007) Induction of immunity to neuroblastoma early after syngeneic hematopoietic stem cell transplantation using a novel mouse tumor vaccine. Biol Blood Marrow Transplant 13: 277-292
28. Kaminitz A, Mizrahi K, Yaniv I, Farkas DL, Stein J, Askenasy N (2009) Low levels of allogeneic but not syngeneic hematopoietic chmerism reverse autoimmune insulitis in prediabetic NOD mice. J Autoimmun 33: 83-91
29. Kamiryo Y, Eto M, Yamada H, Yajima T, Harano M, Takeuchi A, Tatsugami K, Hamaguchi M, Naito S, Yoshikai Y (2009) Donor CD4 T cells are critical in allogeneic stem cell transplantation against murine solid tumor. Cancer Res 69: 5151-5158
30. Kanold J, Paillard C, Tchirkov A, Merlin E, Marabelle A, Lutz P, Rousseau R, Baldomero H, Deméocq F (2008) Allogeneic or haploiden-tical HSCT for refractory or relapsed solid tumors in children: toward a neuroblastoma model. Bone Marrow Transplant 42(Suppl 2): S25-S30
31. Kanold J, Yakouben K, Tchirkov A, Carret AS, Vannier JP, LeGall E, Bordigoni P, Deméocq F (2000) Long-term results of CD34(+) cell transplantation in children with neuroblastoma. Med Pediatr Oncol 35: 1-7
32. Ladenstein R, Pötschger U, Hartman O, Pearson AD, Klingebiel T, Castel V, Yaniv I, Demirer T, Dini G (2008) 28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures. Bone Marrow Transplant 41(Suppl 2): S118-S127
33. Lang P, Pfeiffer M, Müller I, Schumm M, Ebinger M, Koscielniak E, Feuchtinger T, Föll J, Martin D, Handgretinger R (2006) Haploidentical stem cell transplantation in patients with pediatric solid tumors: preliminary results of a pilot study and analysis of graft vs tumor effects. Klin Padiatr 218: 321-326
34. Li JM, Waller EK (2004) Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 10: 540-551
35. Matte CC, Liu J, Cormier J, Anderson BE, Athanasiadis I, Jain D, McNiff J, Shlomchik WD (2004) Donor APCs are required for maximal GVHD but not for GVL. Nat Med 10: 987-992
36. Moyer JS, Maine G, Mulé JJ (2006) Early vaccination with tumor-lysate-pulsed dendritic cells after allogeneic bone marrow transplantation has antitumor effects. Biol Blood Marrow Transplant 12: 1010-1019
37. Naparstek E, Nagler A, Or R, Kapelushnik J, Slavin S (1996) Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies. Clin Transpl 10: 281-290
38. Navid F, Armstrong M, Barfield RC (2009) Immune therapies for neuroblastoma. Cancer Biol Ther 8: 874-882
39. Prigione I, Corrias MV, Airoldi I, Raffaghello L, Morandi F, Bocca P, Cocco C, Ferrone S, Pistoia V (2004) Immunogenicity of human neuroblastoma. Ann NY Acad Sci 1028: 69-80
40. Prigozhina TB, Elkin G, Khitrin S, Slavin S (2008) Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation. Exp Hematol 36: 1750-1759
41. Reddy P, Maeda Y, Liu C, Krijanovski OI, Korngold R, Ferrara JL (2005) A crucial role for antigen-presenting cells and alloantigen expression in graft-vs-leukemia responses. Nat Med 11: 1244-1249
42. Riddell SR, Murata M, Bryant S, Warren EH (2002) Minor histocompat-ibility antigens - targets of graft vs leukemia responses. Int J Hematol 76(Suppl 2): 155-161
43. Ringdén O, Karlsson H, Olsson R, Omazic B, Uhlin M (2009) The allogeneic graft-vs-cancer effect. Br J Haematol 147: 614-633
44. + T cells in low-dose irradiated mice: role of T cell antigen receptor and IL-7 receptor signals. J Immunol 177: 8320-8330
45. Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J, Shlomchik MJ, Emerson SG (1999) Prevention of graft vs host disease by inactivation of host antigen-presenting cells. Science 285: 412-415
46. Slavin S (2001) Immunotherapy of cancer with alloreactive lymphocytes. Lancet Oncol 2: 491-498
47. Slavin S, Or R, Prighozina T, Gurevitch O, Aker M, Panighari S, Shapira M, Nagler A (2000) Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man. Bone Marrow Transplant 25(Suppl 2): S54-S57
48. Tatsuta K, Tanaka S, Tajiri T, Shibata S, Komaru A, Ueda Y, Inoue M, Hasegawa M, Suita S, Sueishi K, Taguchi T, Yonemitsu Y (2009) Complete elimination of established neuroblastoma by synergistic action of gamma-irradiation and DCs treated with rSeV expressing interferon-beta gene. Gene Ther 16: 240-251
49. Teshima T, Mach N, Hill GR, Pan L, Gillessen S, Dranoff G, Ferrara JL (2001) Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. Cancer Res 61: 162-171
50. Valteau-Couanet D, Leboulaire C, Maincent K, Tournier M, Hartmann O, Benard J, Beaujean F, Boccaccio C, Zitvogel L, Angevin E (2002) Dendritic cells for NK/LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients. Blood 100: 2554-2561
51. Verneris MR, Wagner JE (2007) Recent developments in cell-based immune therapy for neuroblastoma. J Neuroimmune Pharmacol 2: 134-139
52. Wolfl M, Jungbluth AA, Garrido F, Cabrera T, Meyen-Southard S, Spitz R, Ernestus K, Berthold F (2005) Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer Immunol Immunother 54: 400-406
53. Wrzesinski C, Restifo NP (2005) Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. Curr Opin Immunol 17: 195-201
54. Xia G, Truitt RL, Johnson BD (2006) Graft-vs-leukemia and graft-vs-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras. Biol Blood Marrow Transplant 12: 397-407
55. Yaniv I, Bouffet E, Irle C, Negrier S, Biron P, Favrot M, Philip I, Brunat-Mentigny M, Philip T (1990) Autologous bone marrow transplantation in pediatric solid tumors. Pediatr Hematol Oncol 7: 35-46
56. Yoshida H, Kusuki S, Hashii Y, Ohta H, Morio T, Ozono K (2009) Ex vivo-expanded donor CD4(+) lymphocyte infusion against relapsing neuroblastoma: a transient graft-vs-tumor effect. Pediatr Blood Cancer 52: 895-897
57. Zöller M (2003) Tumor vaccination after allogeneic bone marrow cell reconstitution of the nonmyeloablatively conditioned tumor-bearing murine host. J Immunol 171: 6941-6953